1. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity;Hughes, J.; Boden, P.; Costall, B.; Domeney, A.; Kelly, E.; Horwell, D.C.;Proc Natl Acad Sci USA,1990
2. Rationally designed 'dipeptoid' analogues of CCK. a-methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties;Horwell, D.C.; Hughes, J.; Hunter, J.C.; Pritchard, M.C.; Richardson, R.S.; Roberts, E.; Woodruff, G.N.;JMedChem,1991
3. PD13430, a selective antagonist ofcholecystokinin type B receptor enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes;Wiesenfeld-Hallin, Z.; Xu, X.J.; Hughes, J.; Horwell, D.C.; Hokfelt, T.;Proc Natl Acad Sci USA,1990
4. Evidence for an involvement of the brain cholecystokinin B;Singh, L.; Lewis, A.S.; Field, M.J.; Hughes, J.; Woodruff, G.N.,1991
5. The effect of CCK-B/gastrin antagonists on stimulated gastric acid secretion in the anaesthetized rat;Hayward, N.J.; Harding, M.; Lloyd, S.A.C.; McKnight, A.T.; Hughes, J.; Woodruff, G.N.;BrJ Pharmacol,1991